FluidAI Medical Raises $15 Million in Series A Funding for AI-driven Postoperative Patient Monitoring

by

FluidAI Medical, a trailblazer in utilizing artificial intelligence (AI) for postoperative patient monitoring, has secured $15 million in Series A funding. The funding round was led by SOSV and Graphene Ventures, with participation from Boutique Venture Partners, Threshold Impact, Cur8 Capital, Leva Capital, Kyto Technology & Life Science Inc., Juno Pharmaceuticals, and several prominent angel investors, funds, and government funding organizations.

Postoperative complications pose significant risks to patients, ranging from infections and bleeding to severe disability or death. Recognizing these complications early is crucial for comprehensive patient care. One of the most devastating complications after surgery is anastomotic leaks, occurring when there’s a connection (anastomosis) between two parts of the digestive tract. These leaks can lead to severe complications, including sepsis and death, with an average mortality rate of 12%.

FluidAI’s solution, the Stream™ Platform, utilizes advanced sensors and an AI-driven algorithm to prompt surgeons to identify these leaks earlier, improving clinical outcomes and streamlining healthcare system efficiencies. The funding highlights the industry’s demand for innovative solutions ensuring patient safety, reduced hospital stays, and decreased healthcare costs.

“This funding not only validates our vision but also fuels our mission. At FluidAI, our goal is to continuously push the boundaries of what’s possible in postoperative care, ensuring patients recover safely and quickly,” said Youssef Helwa, CEO at FluidAI.

“FluidAI is a perfect example of AI-powered proprietary sensing being developed to save lives,” said Duncan Turner, SOSV GP. “We’re thrilled to back the FluidAI team, a passionate group of scientists, engineers, and healthcare professionals who are leading this compelling development in post-operative care.”

The investment will facilitate FluidAI’s expansion into global markets, team growth, intensified R&D efforts, and the introduction of novel AI-driven solutions for various postoperative complications, marking a significant step in revolutionizing medical technology.

Related Stories

Latest News Stories